2017
DOI: 10.1111/jcpt.12586
|View full text |Cite
|
Sign up to set email alerts
|

Pericarditis during infliximab therapy in paediatric ulcerative colitis

Abstract: To our knowledge, this is the first reported paediatric case of pericarditis as a possible complication of infliximab therapy in IBD. Among infliximab-related delayed adverse reactions, cardiac complications should be monitored in the paediatric population.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
10
0
2

Year Published

2018
2018
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 14 publications
(13 citation statements)
references
References 19 publications
1
10
0
2
Order By: Relevance
“…Clinical, endoscopic, or histopathologic signs of exacerbation of UC however did not accompany the second presentation. This corresponds with the previous reports, where the manifestation of pericarditis was not correlated to UC disease activity .…”
Section: Discussionsupporting
confidence: 93%
See 1 more Smart Citation
“…Clinical, endoscopic, or histopathologic signs of exacerbation of UC however did not accompany the second presentation. This corresponds with the previous reports, where the manifestation of pericarditis was not correlated to UC disease activity .…”
Section: Discussionsupporting
confidence: 93%
“…Pericarditis in pediatric IBD patients is rarely reported. So far, we could only identify 12 cases, of which seven were medication induced and four cases showed pericarditis as an extra‐intestinal manifestation of IBD (one unknown case; Table ) .…”
Section: Discussionmentioning
confidence: 99%
“…32 The Food and Drug Administration has approved tumour necrosis factor-alpha (TNF-α) blockers (such as infliximab, adalimumab and golimumab) for the treatment of UC, and the use of these drugs has been associated with worsening of congestive heart failure. 20 Namely, cardiomyopathy has been reported as a severe adverse reaction of adalimumab, 33 34 myocarditis and perimyocarditis have been ascribed to infliximab, [35][36][37] and heart failure onset or worsening has been specified on the safety information of golimumab as new onset or worsening of congestive heart failure have been reported with this compound. 38 Although a cardiac death has been reported in a 66-year-old male 14 days after the first induction dose of vedolizumab (an integrin receptor antagonist currently used to treat UC), it should be emphasised that this patient had a 2-year history of chronic ischaemic heart disease, 39 making unlikely that this drug exerted a toxic effect.…”
Section: Discussionmentioning
confidence: 99%
“…Среди очень редких НР описывались неврит зрительного нерва [47,48], саркоидоз [49], дерматомиозит [50], перикардит [51] и синдром Гийена-Барре [52].…”
Section: Discussionunclassified